Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Periprocedural continuation versus interruption of oral anticoagulant drugs during TAVI
2020-001817-20Phase 4Completed
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of acenocoumarol, phenprocoumon, rivaroxaban, apixaban, dabigatran and 1 more in thromboembolism, Not applicable (see rationale), cardiovascular complications and 2 more (2 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoint: Primary composite endpoint at 30 days. Started Mar 2021; status: completed.
02
Drugs
acenocoumarolphenprocoumonrivaroxabanapixabandabigatran
03
Conditions
thromboembolismNot applicable (see rationale)cardiovascular complicationsaortic stenosis (AS)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2020-001817-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001817-20.